BCRP expression in schwannoma, plexiform neurofibroma and MPNST.

Autor:	de Vries M; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.; Department of Otolaryngology, Leiden University Medical Center, Leiden, The Netherlands., van Tellingen O; Division of Pharmacology/Mouse Cancer Center, The Netherlands Cancer Institute, Amsterdam, The Netherlands., van der Mey AGL; Department of Otolaryngology, Leiden University Medical Center, Leiden, The Netherlands., Bunt AMG; IzumiBiosciences, Inc., Lexington, USA., Bruijn IB; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands., Hogendoorn PCW; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
Jazyk:	angličtina
Zdroj:	Oncotarget [Oncotarget] 2017 Sep 16; Vol. 8 (51), pp. 88751-88759. Date of Electronic Publication: 2017 Sep 16 (Print Publication: 2017).
DOI:	10.18632/oncotarget.21075
Abstrakt:	Background: peripheral nerve sheath tumors comprise a broad spectrum of neoplasms. Vestibular schwannomas and plexiform neurofibromas are symptomatic albeit benign, but a subset of the latter pre-malignant lesions will transform to malignant peripheral nerve sheath tumors (MPNST). Surgery and radiotherapy are the primary strategies to treat these tumors. Intrinsic resistance to drug therapy characterizes all three tumor subtypes. The breast cancer resistance protein BCRP is a transmembrane efflux transporter considered to play a key role in various biological barriers such as the blood brain barrier. At the same time it is associated with drug resistance in various tumors. Its potential role in drug resistant tumors of the peripheral nervous system is largely unknown. Objective: to assess if BCRP is expressed in vestibular schwannomas, plexiform neurofibromas and MPNST. Material and Methods: immunohistochemical staining for BCRP was performed on a tissue microarray composed out of 22 vestibular schwannomas, 10 plexiform neurofibromas and 18 MPNSTs. Results: sixteen out of twenty-two vestibular schwannomas (73%), nine out of ten plexiform neurofibromas (90%) and six out of eighteen MPNST (33%) expressed BCRP in the vasculature. Tumor cells were negative. Conclusion: BCRP is present in the vasculature of vestibular schwannomas, plexiform neurofibromas and MPSNT. Therefore, it may reduce the drug exposure of underlying tumor tissues and potentially cause failure of drug therapy. Competing Interests: CONFLICTS OF INTEREST No potential conflicts of interest were disclosed.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu